Tumor Detection
Tumor Detection - Related Videos
06:23
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
0 Views •
Cited by 8 •
2017
This protocol describes the generation of murine orthotopic bladder tumors in female C57BL/6J mice and the monitoring of tumor growth.
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
0 Views •
Cited by 8 •
2016
This manuscript describes clinical protocols for two next-generation sequencing panels. One panel interrogates hematologic malignancies while the other panel targets genes commonly mutated in solid tumors. Molecular classification of driver mutations in human malignancies offers valuable prognostic and predictive information.
08:30
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
0 Views •
Cited by 18 •
2012
Quantitative Real Time polymerase chain reaction (qPCR) is a rapid and sensitive method to investigate the expression levels of various microRNA (miRNA) molecules in tumor samples. Using this method expression of hundreds of different miRNA molecules can be amplified, quantified, and analyzed from the same cDNA template.
02:39
An In Vivo PET Imaging Technique to Detect Tumors in a Murine Model Using Radiolabeled Antibodies
0 Views •
2025
This video demonstrates a technique involving a radioimmunoconjugate for the in vivo imaging of a tumor in a mouse model. Upon injection of the radioimmunoconjugate, the antibodies of the conjugate bind to a specific membrane antigen on the cancer cells. The radiotracer of the conjugate emits positrons that interact with neighboring electrons to produce energy, which is detected by a positron emission tomography (PET) scanner to create an image of the tumor.
11:02
Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing
0 Views •
Cited by 64 •
2013
We describe the preparation of barcoded DNA libraries and subsequent hybridization-based exon capture for detection of key cancer-associated mutations in clinical tumor specimens by massively parallel "next generation" sequencing. Targeted exon sequencing offers the benefits of high throughput, low cost, and deep sequence coverage, thus yielding high sensitivity for detecting low frequency mutations.
FAQs
Different detection modalities reveal different properties of a suspected tumor. Imaging can localize abnormal tissue, whereas biopsy permits examination of cell morphology. Molecular assays assess changes in genetic material, and immunological assays identify tumor-associated antigens or other characteristic proteins. Combining these readouts helps characterize disease more thoroughly than relying on a single observation.
Antibodies provide a targeted way to examine tumor-associated antigens, which are proteins associated with malignant cells. In an immunological assay, antibody recognition can add cellular or protein-level evidence to imaging and biopsy findings. This targeted signal supports tumor characterization and may help distinguish malignant-cell features from broader inflammatory changes.
Infection can produce inflammation and immune activity that may resemble changes associated with cancer. Separating these possibilities prevents a pathogen-related response from being interpreted as evidence of a tumor, or vice versa. For immunology and infection studies, comparing morphology with molecular and immunological findings provides a stronger basis for interpreting the underlying process.
An evaluation can combine imaging, tissue biopsy, and molecular or immunological assays rather than depend on one measurement. Imaging contributes information about abnormal tissue, biopsy provides cellular material for examination, and the assays test genetic changes or tumor-associated antigens. Together, these steps support characterization, classification, and decisions about subsequent management.
Clinicians and researchers can use findings to support early diagnosis, classify a tumor, select an appropriate treatment, and follow disease over time. Repeated or complementary measurements may indicate whether a tumor is progressing or responding to therapy. Thus, detection is not limited to initial diagnosis; it also contributes to treatment monitoring and assessment.
Within immunology and infection research, tumor detection provides a way to compare cancer-related immune responses with inflammation linked to pathogens. Investigators can integrate tissue appearance with molecular and immune assay results to determine whether observed changes are more consistent with malignant growth or an infectious process. This context improves interpretation of immune findings.